PERCORTEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Percorten, and what generic alternatives are available?
Percorten is a drug marketed by Novartis and is included in two NDAs.
The generic ingredient in PERCORTEN is desoxycorticosterone acetate. There are two drug master file entries for this compound. Additional details are available on the desoxycorticosterone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PERCORTEN?
- What are the global sales for PERCORTEN?
- What is Average Wholesale Price for PERCORTEN?
Summary for PERCORTEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| DailyMed Link: | PERCORTEN at DailyMed |
US Patents and Regulatory Information for PERCORTEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PERCORTEN | desoxycorticosterone pivalate | INJECTABLE;INJECTION | 008822-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Novartis | PERCORTEN | desoxycorticosterone acetate | PELLET;IMPLANTATION | 005151-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
